Here are five things to know:
1. The system is a reverse for fracture arthroplasty system to treat proximal humeral fractures.
2. In addition to the FDA approval, the first surgeries using the system have been completed.
3. The system is designed to improve tuberosity fixation and healing.
4. The company plans for a larger commercial release of the system in 2025.
5. Catalyst OrthoSciences raised $20 million in financing in September.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
